VivoSeq
Neurology

Tardive Dyskinesia

22

Pipeline Programs↗

4

Active Trials↗

15

Companies Involved↗

Tardive Dyskinesia is an emerging landscape with 22 programs across 15 companies. The most active players are Luye Pharma Group Ltd., Auspex Pharmaceuticals, Inc., Tanabe Pharma Corporation. 9 therapies are approved with 7 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

48/100

Pipeline Velocity

15/100

Mech. Concentration

11/100

Completion Rate

75/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Luye Pharma Group Ltd. logo

Luye Pharma Group Ltd.

1 program

Phase 2A

Auspex Pharmaceuticals, Inc.

1 program

Phase 3Tanabe Pharma Corporation logo

Tanabe Pharma Corporation

1 program

Phase 3Merck & Co. logo

Merck & Co.

1 program

Phase 3Mylan Pharmaceuticals Inc logo

Mylan Pharmaceuticals Inc

1 program

Phase 3Eli Lilly logo

Eli Lilly

1 program

Phase 3

Pipeline

Programs by Phase

Analysis

Trial Status

33

clinical trials

Completed21 · 64%
Withdrawn5 · 15%
Recruiting4 · 12%
Terminated2 · 6%
Unknown status1 · 3%

Clinical Trials

Trial Activity

33 trials

Safety and Efficacy of LPM3770164 Sustained-release Tablets in Patients With Tardive Dyskinesia
Recruiting·Luye Pharma Group Ltd. logoLuye Pharma Group Ltd.·Phase 1/2·NCT06731868·120 enrolled
A Study to Evaluate the Effectiveness of Valbenazine in Adult Participants With Tardive Dyskinesia (TD) Who Remain Symptomatic While Receiving or After Stopping a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor
Recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 4·NCT07105111·50 enrolled
Identification, Assessment, and Treatment of Tardive Dyskinesia With Deutetrabenazine in Adults With Intellectual/Developmental Disabilities and Co-occurring Psychiatric and/or Behavioral Disorders
Recruiting·UUniversity Hospitals Cleveland Medical Center·Approved·NCT06997198·25 enrolled
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, and Tolerability of NBI-1065890 in Adult Participants With Tardive Dyskinesia
Recruiting·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 2·NCT07365462·100 enrolled
Tardive Dyskinesia and Cognitive Function
Completed·TTaipei Veterans General Hospital, Taiwan·Phase 4·NCT00926965·80 enrolled
Levetiracetam in the Treatment of Neuroleptic-induced Tardive Dyskinesia
Completed·UCB logoUCB·Phase 2·NCT00175955·70 enrolled
Ethyl-Eicosapentaenoic Acid and Tardive Dyskinesia
Completed·UUniversity of Stellenbosch·Phase 4·NCT00114595·84 enrolled
Study of the Effectiveness of Valbenazine on Patient- and Clinician-Reported Outcomes in Participants With Tardive Dyskinesia
Completed·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 4·NCT05859698·59 enrolled
Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia
Completed·Tanabe Pharma Corporation logoTanabe Pharma Corporation·Phase 2/3·NCT03176771·256 enrolled
Extract of Ginkgo Biloba and Tardive Dyskinesia
Completed·—·Phase 3·NCT00672373·157 enrolled
Aim to Reduce Movements in Tardive Dyskinesia
Completed·AAuspex Pharmaceuticals, Inc.·Phase 2/3·NCT02195700·117 enrolled
Treatment of Tardive Dyskinesia With Galantamine
Completed·—·Phase 4·NCT00164242·36 enrolled
Levetiracetam Treatment of Tardive Dyskinesia
Completed·YYale University·Phase 3·NCT00291213·50 enrolled
Risperidone and Olanzapine for the Schizophrenic Patients With Neuroleptic-Induced Tardive Dyskinesia
Completed·Taoyuan Psychiatric Center, Ministry of Health and Welfare, Executive Yuan, R.O.C. Taiwan·Phase 4·NCT00621998·60 enrolled
A Phase 3 Study of NBI-98854 for the Treatment of Tardive Dyskinesia
Completed·Neurocrine Biosciences logoNeurocrine Biosciences·Phase 3·NCT02274558·234 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)